Search results
Trials that infected people with common colds can inform today’s COVID-19 challenge trials
Nature· 4 days agoLetter to the Editor
Could FLiRT Variants Cause Another Covid-19 Surge?
Forbes· 3 days agoA new Covid-19 variant known as KP.2, or FLiRT, began to emerge in the United States in early March of this year. This dramatic rise signals that KP.2...
Mystery Finally Solved? New Discovery Could Explain Long COVID
SciTechDaily· 5 days agoResearchers at UVA Health have uncovered a potential explanation for some of the most puzzling...
Invivyd appoints two new directors to its board By Investing.com
Investing.com· 2 days agoInvivyd Inc. (NASDAQ:IVVD), a biopharmaceutical company, announced the election of two new...
From infection to chronic illness: Learning from long COVID
Medical Xpress· 4 days agoWhile there are known links between bacterial and viral infections with post-acute infection syndromes, much is still unknown about the mechanisms that underpin these illnesses or why they occur ...
TB has reclaimed its place as the world’s biggest infectious killer – but are its days numbered?
The Telegraph via Yahoo News· 4 days agoIn the few minutes it takes to read this article, some 15 people are likely to have died from...
NanoViricides Bolsters Partnership Efforts - Engages Aagami Inc.
Morningstar· 1 day agoSHELTON, CT / ACCESSWIRE / May 23, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical-stage global leader in broad-spectrum antiviral nanomedicines, reports that it ...
NanoViricides Bolsters Partnership Efforts - Engages Aagami Inc.
The Kansas City Star· 1 day agoSHELTON, CT / ACCESSWIRE / May 23, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical-stage global leader in broad-spectrum antiviral nanomedicines, reports that it ...
New COVID-19 'FLiRT' Variants Are The Most Dominant In The U.S.
Women s Health· 3 days agoA new set of COVID-19 variants—which have been given the nickname FLiRT—are the new dominant strain in the United States, currently accounting for 28.2% of all cases, the ...
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and...
The Yuma Sun· 4 days agoThe efficacy of ARCT-154 against severe COVID...